国药现代(600420) - 2025 Q2 - 季度业绩

Key Financial Data and Indicators In the first half of 2025, the company's core financial indicators showed a downward trend, with total operating revenue decreasing by 18.16% and net profit attributable to shareholders declining by 6.46%, while shareholders' equity and net assets per share saw slight growth Key Financial Data and Indicators for the Current Reporting Period | Item | Current Reporting Period (RMB) | Prior Year Same Period (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 4,877,673,521.93 | 5,960,093,922.86 | -18.16 | | Operating Profit | 920,163,725.85 | 1,096,704,023.68 | -16.10 | | Total Profit | 924,926,954.05 | 1,086,401,902.24 | -14.86 | | Net Profit Attributable to Shareholders of Listed Company | 672,066,877.31 | 718,477,263.45 | -6.46 | | Basic Earnings Per Share (RMB/share) | 0.5011 | 0.5357 | -6.46 | Key Financial Data and Indicators at the End of the Current Reporting Period | Item | End of Current Reporting Period (RMB) | Beginning of Current Reporting Period (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 19,658,833,692.75 | 19,955,597,470.69 | -1.49 | | Shareholders' Equity Attributable to Shareholders of Listed Company | 13,643,330,466.99 | 13,203,924,172.51 | 3.33 | | Net Assets Per Share (RMB/share) | 10.17 | 9.85 | 3.25 | Explanation of Operating Performance and Financial Condition During the reporting period, the company experienced declines in both revenue and profit, primarily due to market supply-demand shifts affecting penicillin-related raw materials and intermediates, alongside reduced sales of certain preparations due to centralized drug procurement and decreased demand, yet managed to stabilize profitability through strategic focus, R&D, and cost control - Sales volume and prices of certain penicillin-related raw materials and intermediates decreased year-on-year due to market supply and demand fluctuations[7] - Sales revenue for certain cephalosporin, hormone, and neurological products in the preparation business declined year-on-year due to centralized drug procurement and reduced end-user demand[7] - The company significantly reduced period expenses and stabilized its profit margin through strategic focus, R&D advancement, market penetration, and cost reduction initiatives[7] Risk Warning The company explicitly states that the financial data in this performance express report are preliminary and unaudited, potentially differing from the final audited data in the semi-annual report, cautioning investors about associated investment risks - The key financial data for the first half of 2025 contained in this announcement are preliminary and unaudited by an accounting firm[2][8] - The final specific data will be subject to the company's 2025 semi-annual report, and investors are advised to be aware of investment risks[8]